Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by peterdrillingon Apr 16, 2018 10:41pm
81 Views
Post# 27895021

RE:A $0.50 target = $500 million market cap

RE:A $0.50 target = $500 million market capThis coming from a board member who has been ignored 75 times. Financing will come soon enough. All shorts welcome not to cover once money flows in. Boston Scientific does not own 22% for nothing. Inventor funded $7 mill last week for a reason. The company paid off over $100 million in lawsuits instead of closing the doors for a reason. FDA approved products and they cannot keep up with the German applications. Revenue expected to increase at an average rate of 45% yearly. Implants to increase more than 3000% by Q3 2019 and I can continue but you can find this info anywhere. So shorts, stay as long as you like. Patient is key here and read on companies CURRENT EVENTS. The above written is all factual and not opinion related.

<< Previous
Bullboard Posts
Next >>